In addition, the expression of C-MYC, Cyclin D1, Bcl-2, Bcl-xL, COX-2, TWIST1, and MMP2, which are associated with NF-κB signaling, was analyzed to better understand the NF-κB pathways involved in inhibiting lung cancers and was obviously decreased by 160 μM EGCG (Fig. 2G-H). The gene discussed is BCL2L1; the disease is lung carcinoma.